{"id":443,"date":"2026-09-14T13:53:13","date_gmt":"2026-09-14T11:53:13","guid":{"rendered":"https:\/\/asmed.net\/?page_id=443"},"modified":"2026-09-22T19:29:47","modified_gmt":"2026-09-22T17:29:47","slug":"processi-riparativi-e-rigenerativi","status":"publish","type":"page","link":"https:\/\/asmed.net\/en\/tecnologia\/indicazioni-terapeutiche\/processi-riparativi-e-rigenerativi\/","title":{"rendered":"Reparative and regenerative processes"},"content":{"rendered":"

\nTherapeutic indications \u00b7 Reparative and regenerative processes\n<\/p>

\nRestorative and regenerative processes: when tissue recovery slows down.\n<\/h1>

\nFor the doctor following tissue injury and suffering \u2014 in surgery, dermatology, orthopedics, sports medicine \u2014 when repair times affect the entire pathway, and consider a complementary, non-invasive, drug-free option. On this page: what exists, what has been studied, with what limits.\n<\/p><\/div><\/section>

\nIn practice\n<\/p>

\nWhen recovery times affect the route\n<\/h2>

\nIn some patients, tissue repair proceeds more slowly than the injury would have predicted: wounds and ulcers that are difficult to close, muscle and tendon injuries that do not consolidate, edema and inflammation that persist beyond the expected time.\n<\/p>

\nWhen it happens, the path stretches for everyone: more dressings and controls, delay in rehabilitation, functional and aesthetic outcomes that the patient lives as definitive. And the tools that directly affect repair processes remain few.\n<\/p>

\nIt is in this space that it makes sense to consider a complementary \u2013 non-invasive \u2013 option, applicable on intact skin alongside the standard treatment, with protocols defined by tissue type and depth.\n<\/p><\/div>

\"Three-dimensional<\/div><\/div><\/section>

\nWhat exists\n<\/p>

\nREAC\u00ae protocols for this area\n<\/h2>

\nFor the reparative and regenerative processes, REAC\u00ae Technology provides the biomodulation protocols of the Tissue Optimization family, applied with the medical device BENE Mod 110. The scope, as defined in the technical documentation, includes conditions characterised by impaired tissue recovery and regeneration capacity in tissue injury and suffering.\n<\/p><\/div>

\n01\n<\/span>

\nTO-RPR \u2014 Tissue Optimization Reparative\n<\/h3>

\nSurface application with the ACP electrode on the area to be treated, 15 or 30 minutes per session according to the clinical picture, in cycles of an average of 18 sessions. For the reparative processes of medium and deep tissues with prevalence of the inflammatory component. Reserved for doctors.\n<\/p><\/div>

\n02\n<\/span>

\nACT, CO, MO \u2014 Anti-inflammation Cellular Treatment, Circulation Optimization, Metabolic Optimization\n<\/h3>

\nApplicazione di superficie con l'elettrodo ACP sulla zona da trattare, 15 minuti per seduta, in cicli mediamente di 18 sedute. Per i processi riparativi in cui prevalgono alterazioni infiammatorie, microcircolatorie o metaboliche; secondo la documentazione tecnica \u00e8 la modalit\u00e0 consigliata nei processi infiammatori acuti. Riservati ai medici.\n<\/p><\/div>

\n03\n<\/span>

\nACT-IBZ, CO-IBZ, MO-IBZ \u2014 Inside Blue Zone variants\n<\/h3>

\nGli stessi tre protocolli nella variante da 30 minuti per seduta, in cicli mediamente di 9 sedute: secondo la documentazione tecnica \u00e8 la modalit\u00e0 consigliata nei processi infiammatori cronici. Stessa applicazione di superficie con l'elettrodo ACP. Riservati ai medici.\n<\/p><\/div><\/div>

\nThe treatment is painless and takes place on intact skin; according to the technical documentation, no contraindications to the concomitant use of pharmacological therapies are known.\n<\/p>

\nDevice and Protocols \u2192\n<\/a><\/div><\/div><\/section>

\nWhat literature says\n<\/p>

\nWhat has been studied\n<\/h2>

\nEleven clinical publications by Rinaldi and Fontani (2011\u20132026) on reparative processes, plus in vitro and animal model studies, are indexed on PubMed. These include: a three-arm randomized trial, a prospective observational post-market clinical follow-up study, an interventional study without control group, and several case reports. Here the main ones, with design and number.\n<\/p><\/div>

\nREAC-induced endogenous bioelectric currents in the treatment of venous ulcers: a three-arm randomized controlled prospective study\n<\/h3>

\nActa Dermatovenerologica Alpina, Pannonica et Adriatica \u00b7 2020\n<\/p>

\nRandomized, controlled, prospective, three-armed \u00b7 30 patients with venous ulcers of the lower extremities \u00b7 TO-RPR in addition to the standard dressing, with or without elastic compression, against dressing and compression alone \u00b7 healing, perceived pain, quality of life.\n<\/p>\nView on PubMed \u2192\n<\/a><\/article>

\nClinical Performance of REAC-Based ACT, CO, and MO-IBZ Protocols in Routine Practice: A Prospective Real-World Observational PMCF Study\n<\/h3>

\nJournal of Clinical Medicine \u00b7 2026\n<\/p>

\nProspective observational (PMCF), without control group \u00b7 50 subjects in routine clinical practice \u00b7 ACT, CO and MO in sequence \u00b7 pain (VAS) at initiation, end of treatment and follow-up; sleep, fatigue and general perceived state by severity categories \u00b7 no adverse events reported.\n<\/p>\nView on PubMed \u2192\n<\/a><\/article>

\nREAC neurobiological treatments in acute post-traumatic knee medial collateral ligament lesion\n<\/h3>

\nHeliyon \u00b7 2020\n<\/p>

\nInterventional, without control group \u00b7 45 subjects with acute medial collateral ligament injury of the knee \u00b7 one NPO session and 18 TO sessions within 4 days of trauma \u00b7 clinical evaluation at four time points, 30-day follow-up \u00b7 comparison only with usual practice times.\n<\/p>\nView on PubMed \u2192\n<\/a><\/article>

\nFunctional Recovery After 18 Sessions of REAC Tissue Optimization Reparative Protocol for Hill-Sachs Lesion in a Post-traumatic Shoulder Dislocation\n<\/h3>

\nCureus \u00b7 2025\n<\/p>

\nCase report \u00b7 a 22-year-old patient \u00b7 18 TO-RPR sessions \u00b7 pain (NRS), joints, strength; MRI at 4 months.\n<\/p>\nView on PubMed \u2192\n<\/a><\/article><\/div>

\nThe limits to know: The only randomized trial had 30 patients divided into three groups. the PMCF study has no control group and is conducted by the inventors of the technology; the rest of the clinical literature is made up of case reports and small series; in vitro and animal model studies document mechanisms, not clinical outcomes.\n<\/p>

\nAll publications on PubMed\n<\/a><\/div><\/div><\/section>

\nFrequently Asked Questions\n<\/p>

\nBefore evaluating it: the most frequently asked questions\n<\/h2><\/div>
\n
\n

\n